A new approach to determine tumor-to-blood 10B concentration ratios from the clinical outcome of a BNCT treatment

Applied Radiation and Isotopes

Volumn 61, Issue 5, 2004, Pages 923-928

  Gonzalez S J ^a   Carando, D G ^b   Bonomi, M R ^c  

^a Department of Radiobiology   (Argentina)

^b UNIVERSIDAD DE SAN ANDRÉS   (Argentina)

^c Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Maximum likelihood estimation; Nodular melanoma; Pharmacokinetics

Indexed keywords

DOSIMETRY; MEDICAL IMAGING; NEUTRON BEAMS; PATIENT TREATMENT; STATISTICAL METHODS; TRANSPLANTATION (SURGICAL);

BORON NEUTRON CAPTURE THERAPY (BNCT); MULTIPLE NODULAR MELANOMAS; TUMOR-TO-BLOOD CONCENTRATION RATIO;

TISSUE;

BORON 10;

CANCER CONTROL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONFIDENCE INTERVAL; DOSIMETRY; DRUG BLOOD LEVEL; DRUG TUMOR LEVEL; HUMAN; LITERATURE; MELANOMA; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; SKIN DISEASE; STATISTICAL ANALYSIS;

BORON; BORON NEUTRON CAPTURE THERAPY; CONFIDENCE INTERVALS; HUMANS; ISOTOPES; LIKELIHOOD FUNCTIONS; MELANOMA; MODELS, BIOLOGICAL; RADIOTHERAPY DOSAGE;

EID: 4143115762     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2004.05.069     Document Type: Conference Paper

References (9)

1. Blaumann H.R., González S.J., Longhino J., Santa Cruz G.A., Calzetta Larrieu O.A., Bonomi M.R., Roth B.M.C. Boron neutron capture therapy of skin melanomas at the RA-6 reactor. a procedural approach to beam set up and performance evaluation for upcoming clinical trials Med. Phys. 31(1):2004;70-80
2. Coderre J.A., Chanana A.D., Joel D.D., Elowitz E.H., Micca P.L., Nawrocky M.M., Chadha M., Gebbers J.O., Shady M., Peress N.S., Slarkin D.N. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme. boron concentration correlates with tumor cellularity Radiat. Res. 149:1998;163-170
3. 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients. a study of boron neutron capture therapy for malignant melanoma Radiat. Res. 9:1999;75-83
4. González S.J., Santa Cruz G.A., Kiger W.S. III, Goorley J.T., Palmer M.R., Busse P.M., Zamenhof R.G. NCTPlan, the New PC version of MacNCTPlan: Improvements and Verification of a BNCT Treatment Planning System. Sauerwein W., Moss R., Wittig A. Proceedings of the Tenth International Congress on Neutron Capture Therapy. 2002;557-561 Monduzzi Editore, Bologna
5. González, S.J., Bonomi, M.R., Santa Cruz, G.A., Blaumann, H.R., Calzetta Larrieu, O.A., Menéndez, P., Jiménez Rebagliati, R., Longhino, J., Feld, D.B., Dagrosa, M.A., Argerich, C., Castiglia, S.G., Batistoni, D.A., Liberman, S.J., Roth, B.M.C., 2004. First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome. Appl. Rad. Isot., this issue, doi:10.1016/j.apradiso.2004.05.060.
6. Liberman, S.J., Dagrosa, M.A., Jimenez Rebagliati, R., Bonomi, M.R., Roth, B.M.C., Turjanski, L., Castiglia, S.G., González, S.J., Menéndez, P., Cabrini, R., Roberti, M.J., Batistoni, D.A., 2004. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl. Rad. Isot., this issue, doi:10.1016/j. apradiso.2004.05.013.
7. Mallesch J.L., Moore D.E., Allen B.J., McCarthy W.H., Jones R., Stening W. The pharmacokinetics of p-boronophenylalanine.fructose in human patients with glioma and metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;1183-1188
8. Overgaard J., Overgaard M., Vejby Hansen P., von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother. Oncol. 12:1986;867-872
9. Rice, J.A., 1995. Mathematical Statistics and Data Analysis. Duxbury Press, Belmont, CA.